CEACAM5 and colorectal carcinoma: The carcinoembryonic antigen (CEA) marker is utilized to monitor treatment response in patients with CRC, while the Fecal Occult Blood Test (FOBT) has been employed for screening high-risk populations; however, its sensitivity and specificity, particularly for proximal CRC, are limited [36].